Am J Perinatol 2021; 38(05): 421-427
DOI: 10.1055/s-0040-1718371
SMFM Fellowship Series Article

The Use of Sequential Integrated Screening to Stratify Risk in Monochorionic-Diamniotic Twin Pregnancies

Edward Miller
1   Division of Maternal–Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California
,
Cinthia Blat
1   Division of Maternal–Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California
,
Kristen Gosnell
1   Division of Maternal–Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California
,
Juan Gonzalez
1   Division of Maternal–Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California
,
Neda Ghaffari
1   Division of Maternal–Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California
› Author Affiliations
Funding None.

Abstract

Objective This study aimed to identify differences in sequential integrated screening and early ultrasound markers in monochorionic/diamniotic (MC/DA) pregnancies complicated by twin-to-twin transfusion syndrome (TTTS) and unequal placental sharing (UPS).

Study Design Retrospective cohort study of MC/DA pregnancies evaluated between January 2012 and July 2017 at the University of California San Francisco. MC/DA pregnancies with ultrasound surveillance up to 26 weeks who participated in the California Prenatal Screening Program (CPSP) were included. Pregnancies with structural or genetic anomalies were excluded. UPS was defined as an intertwin growth discordance ≥20%. Intertwin nuchal translucency (NT) discordance was calculated by the absolute value of the difference of the NT of cotwins. Kruskal–Wallis or ANOVA testing was performed where appropriate, and negative binomial regression models were chosen to test for differences in mean biomarker levels by outcome group.

Results A total of 191 MC/DA pregnancies were included; 85 were affected by TTTS, 35 by UPS, and 71 controls. Significant differences in intertwin NT discordance in pregnancies complicated by TTTS and UPS compared with controls (p = 0.007) were found. TTTS cases had a mean NT discordance greater than two times that of controls (p = 0.04), while UPS cases had a value more than three times greater (p = 0.003). There was a statistically significant difference in mean second trimester human chorionic gonadotropin (hCG) between the cohorts (p = 0.0002) with TTTS cases having a mean second trimester hCG value 1.5 greater than both controls (p < 0.001) and UPS cases (p = 0.001). Analysis showed a significant difference in mean second trimester inhibin between the three cohorts (p = 0.029). Pregnancies complicated by UPS had a mean second trimester inhibin 1.5 times greater than controls (p = 0.010).

Conclusion Our study shows that there are unique differences in early ultrasound and sequential integrated serum markers between MC/DA gestations complicated by TTTS and UPS versus those unaffected.

Key Points

  • Differences exist in sequential integrated screening markers in monochorionic-diamniotic twin pregnancies.

  • Early risk stratification of monochorionic-diamniotic twin pregnancies may be possible.

  • Sequential integrated screening testing can provide useful information to clinicians when evaluating monochorionic-diamnitoic twin pregnancies.



Publication History

Received: 13 May 2020

Accepted: 25 August 2020

Article published online:
08 October 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Chasen T, Stephen M, Chervenak A, Frank MD. In: Barss VA. ed. Twin Pregnancy: Prenatal Issues, in Up to Date. Waltham, MA: 2018
  • 2 Sueters M, Oepkes D. Diagnosis of twin-to-twin transfusion syndrome, selective fetal growth restriction, twin anaemia-polycythaemia sequence, and twin reversed arterial perfusion sequence. Best Pract Res Clin Obstet Gynaecol 2014; 28 (02) 215-226
  • 3 Mackie FL, Morris RK, Kilby MD. The prediction, diagnosis and management of complications in monochorionic twin pregnancies: the OMMIT (Optimal Management of Monochorionic Twins) study. BMC Pregnancy Childbirth 2017; 17 (01) 153
  • 4 Ville Y. Twin-to-twin transfusion syndrome: time to forget the Quintero staging system?. Ultrasound Obstet Gynecol 2007; 30 (07) 924-927
  • 5 Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore TR, Greene MF. Invasive Fetal, eds. Therapy in Creasy and Resnik's Maternal-Fetal Medicine Principles and Practice. Philadelphia, PA: Saunders/Elsevier; 2014
  • 6 Johnson A. Diagnosis and management of twin-twin transfusion syndrome. Clin Obstet Gynecol 2015; 58 (03) 611-631
  • 7 Huber A, Diehl W, Bregenzer T, Hackelöer BJ, Hecher K. Stage-related outcome in twin-twin transfusion syndrome treated by fetoscopic laser coagulation. Obstet Gynecol 2006; 108 (02) 333-337
  • 8 Khalil A, Rodgers M, Baschat A. et al. ISUOG practice guidelines: role of ultrasound in twin pregnancy. Ultrasound Obstet Gynecol 2016; 47 (02) 247-263
  • 9 Lewi L, Lewi P, Diemert A. et al. The role of ultrasound examination in the first trimester and at 16 weeks' gestation to predict fetal complications in monochorionic diamniotic twin pregnancies. Am J Obstet Gynecol 2008; 199 (05) 493.e1-493.e7
  • 10 Linskens IH, de Mooij YM, Twisk JW, Kist WJ, Oepkes D, van Vugt JM. Discordance in nuchal translucency measurements in monochorionic diamniotic twins as predictor of twin-to-twin transfusion syndrome. Twin Res Hum Genet 2009; 12 (06) 605-610
  • 11 Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH. Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 2007; 29 (05) 527-532
  • 12 Dugoff L. Society for Maternal-Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010; 115 (05) 1052-1061
  • 13 Linskens IH, Engels M, Oepkes D, Heijboer AC, Blankenstein MA, van Vugt JM. A trend toward increased first trimester free beta-hCG and PAPP-A in monochorionic twins complicated by twin-to-twin transfusion syndrome. Prenat Diagn 2010; 30 (09) 909-910
  • 14 Dyr B, Boomer T, Almasri EA. et al. A new era in aneuploidy screening: cfDNA testing in >30,000 multifetal gestations: experience at one clinical laboratory. PLoS One 2019; 14 (08) e0220979
  • 15 ACOG Committee Opinion No. 640: cell-free DNA screening for fetal aneuploidy. Obstet Gynecol 2015; 126 (03) 691-692
  • 16 Flessel MC, Lorey FW. The California Prenatal Screening Program: “options and choices” not “coercion and eugenics”. Genet Med 2011; 13 (08) 711-713
  • 17 Blumenfeld YJ, Taylor J, Lee HC, Hudgins L, Sung JF, El-Sayed YY. Utilization of available prenatal screening and diagnosis: effects of the California screen program. J Perinatol 2012; 32 (12) 907-912
  • 18 Dias T, Arcangeli T, Bhide A, Napolitano R, Mahsud-Dornan S, Thilaganathan B. First-trimester ultrasound determination of chorionicity in twin pregnancy. Ultrasound Obstet Gynecol 2011; 38 (05) 530-532
  • 19 Simpson LL. Society for Maternal-Fetal Medicine. Twin-twin transfusion syndrome. Am J Obstet Gynecol 2013; 208 (01) 3-18
  • 20 Fick AL, Feldstein VA, Norton ME, Wassel Fyr C, Caughey AB, Machin GA. Unequal placental sharing and birth weight discordance in monochorionic diamniotic twins. Am J Obstet Gynecol 2006; 195 (01) 178-183
  • 21 Spencer K, Cowans NJ, Avgidou K, Nicolaides KH. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 2006; 28 (05) 637-643
  • 22 Gagnon A, Wilson RD. Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30 (10) 918-932
  • 23 Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den Hof M. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 2003; 189 (03) 775-781
  • 24 Rosner JY, Fox NS, Saltzman D, Klauser CK, Rebarber A, Gupta S. Abnormal biochemical analytes used for aneuploidy screening and adverse pregnancy outcomes in twin gestations. Am J Perinatol 2015; 32 (14) 1331-1335
  • 25 ACOG Practice Bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol 2016; 127 (05) e123-e137
  • 26 Norwitz ER, McNeill G, Kalyan A. et al. Validation of a single-nucleotide polymorphism-based non-invasive prenatal test in twin gestations: determination of zygosity, individual fetal sex, and fetal aneuploidy. J Clin Med 2019; 8 (07) 8